CN111995169A - Novel treatment device and treatment method for pharmaceutical wastewater - Google Patents
Novel treatment device and treatment method for pharmaceutical wastewater Download PDFInfo
- Publication number
- CN111995169A CN111995169A CN202010659945.XA CN202010659945A CN111995169A CN 111995169 A CN111995169 A CN 111995169A CN 202010659945 A CN202010659945 A CN 202010659945A CN 111995169 A CN111995169 A CN 111995169A
- Authority
- CN
- China
- Prior art keywords
- wastewater
- peroxymonosulfate
- bioreactor
- mbr
- pharmaceutical wastewater
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F9/00—Multistage treatment of water, waste water or sewage
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/52—Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities
- C02F1/54—Treatment of water, waste water, or sewage by flocculation or precipitation of suspended impurities using organic material
- C02F1/56—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/66—Treatment of water, waste water, or sewage by neutralisation; pH adjustment
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/72—Treatment of water, waste water, or sewage by oxidation
- C02F1/722—Oxidation by peroxides
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F3/00—Biological treatment of water, waste water, or sewage
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F3/00—Biological treatment of water, waste water, or sewage
- C02F3/28—Anaerobic digestion processes
- C02F3/2846—Anaerobic digestion processes using upflow anaerobic sludge blanket [UASB] reactors
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F3/00—Biological treatment of water, waste water, or sewage
- C02F3/32—Biological treatment of water, waste water, or sewage characterised by the animals or plants used, e.g. algae
- C02F3/322—Biological treatment of water, waste water, or sewage characterised by the animals or plants used, e.g. algae use of algae
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Hydrology & Water Resources (AREA)
- Engineering & Computer Science (AREA)
- Environmental & Geological Engineering (AREA)
- Water Supply & Treatment (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Abstract
The invention discloses a novel treatment device and a novel treatment method for pharmaceutical wastewater, and belongs to the technical field of sewage treatment. The method comprises the steps of firstly directly carrying out oxidative degradation on pharmaceutical wastewater to be treated by using peroxymonosulfate, then flocculating and settling the wastewater in a sedimentation tank under the action of a coagulant aid, and then sequentially enabling the wastewater to enter an anaerobic bioreactor and an MBR (membrane bioreactor) coupled with an algae system for treatment.
Description
Technical Field
The invention relates to a novel treatment device and a treatment method for pharmaceutical wastewater, belonging to the technical field of sewage treatment.
Background
With the increasing aging phenomenon of the population in China and the importance of people on the health concept, the requirements of people on rehabilitation, health care and medical treatment are getting larger and larger, and the pharmaceutical industry is rapidly developed. At present, China becomes one of global chemical raw material medicine production, export big countries and global big pharmaceutical preparation production countries. Meanwhile, pharmaceutical wastewater is produced in large quantities. According to the annual book of 2016 Chinese environmental statistics, by 2015, the number of pharmaceutical manufacturing enterprises in China reaches 3874, the total amount of discharged wastewater in the pharmaceutical industry reaches 53259 ten thousand tons, and the total amount of discharged wastewater accounts for 2.93 percent of the total amount of discharged industrial wastewater. The pharmaceutical industry products have various types and complex processes. The pharmaceutical wastewater has complex components, strong toxicity, high organic matter concentration, high chromaticity, large pH value fluctuation, high nitrogen and phosphorus content, large water quality fluctuation and difficult biodegradation. If the water is treated improperly, the water is discharged into a natural water body, so that not only can serious water pollution problem be caused, the ecological balance of the water body be damaged, and the self-cleaning function of the water body be influenced, but also the water can continuously enter organisms and human bodies through a food chain and a food net, and inestimable harm is brought to the health of aquatic plants, animals and human beings. Therefore, the pharmaceutical wastewater is one of industrial wastewater which is seriously polluted and difficult to treat in China.
In the 40 th of the 20 th century, physical and chemical methods such as neutralization, precipitation, oxidation and the like are adopted in the earliest in the United states to simply treat pharmaceutical industrial wastewater; in the 20 th century and 50 s, the advanced treatment of aerobic organisms is gradually started; in the 20 th century from 60 s to 70 s, biochemical treatment technologies such as pure oxygen aeration and tower biofilters have become development trends; after the 70's of the 20 th century, research on pharmaceutical industry wastewater treatment developed rapidly in developing countries. At present, a plurality of methods are commonly used at home and abroad or the traditional process is strengthened to treat the pharmaceutical wastewater, but the conventional treatment method has the problems of complex operation, high cost, unstable and unexpected water outlet effect and the like. Therefore, a method for treating pharmaceutical wastewater with simple operation, low cost and good water outlet effect is needed.
Disclosure of Invention
The method comprises the steps of firstly, directly carrying out oxidative degradation on pharmaceutical wastewater to be treated by using peroxymonosulfate, then, carrying out flocculation and sedimentation on the wastewater in a sedimentation tank under the action of a coagulant aid, and then, sequentially enabling the wastewater to enter an anaerobic bioreactor and an MBR (membrane bioreactor) coupled with an algae system for treatment.
In order to achieve the technical purpose, the technical scheme of the invention is as follows:
a novel treatment device for pharmaceutical wastewater comprises a peroxymonosulfate oxidation tank, a sedimentation tank, a UASB anaerobic bioreactor and an MBR membrane bioreactor which are sequentially connected in series from upstream to downstream; a light source and an aeration device are arranged in the MBR membrane bioreactor, and microalgae are uniformly distributed in the activated sludge in the MBR membrane bioreactor.
The method for treating the pharmaceutical wastewater by adopting the device comprises the following steps:
(1) introducing the pharmaceutical wastewater to be treated into a peroxymonosulfate oxidation tank, and then adding peroxymonosulfate into the peroxymonosulfate oxidation tank for reaction;
(2) adjusting the pH of effluent of a peroxymonosulfate oxidation tank to 7-8 by adopting a pH regulator, then adding a coagulant aid into the wastewater, and after fully stirring, allowing the wastewater to enter a sedimentation tank for sedimentation for 20-30 min;
(3) introducing effluent of the sedimentation tank into a UASB anaerobic bioreactor, and carrying out anaerobic treatment under the conditions that the pH is 6.5-7.5 and the temperature is 35 ℃;
(4) and (3) introducing the effluent of the anaerobic bioreactor into an MBR (membrane bioreactor) for treatment, and directly discharging the effluent.
Preferably, the adding amount of the peroxymonosulfate in the step (1) is 100-1200 mu mol/L, and the ratio of the adding amount of the peroxymonosulfate to the initial concentration of the antibiotics in the pharmaceutical wastewater is 100 mu mol/L (2-3) mg/L.
Preferably, the pH regulator in step (2) is HCl solution or Ca (OH)2And (4) suspending the solution.
Preferably, the coagulant aid in the step (2) is polyacrylamide, and the dosage of the coagulant aid is 3 mg/L.
Preferably, the UASB anaerobic bioreactor in step (3) is filled with polyethylene plastic rings as microorganism carriers.
Preferably, the concentration of the activated sludge in the MBR membrane reactor in the step (4) is 6-8 g/L, and the mass ratio of the microalgae to the activated sludge is 10: 1.
Preferably, the membrane flux of the MBR membrane reactor in the step (4) is 6-10L/(m)2And/h), the HRT of the MBR membrane reactor hydraulic retention time is 8-10 h, and the SRT of the sludge retention time is 15-25 d.
Preferably, the aeration rate in the MBR membrane reactor in the step (4) is controlled to be 2L/m3The illumination intensity of the light source is 300 mu mol/(m)2S), light-to-dark ratio of 12h: and (4) 12 h.
Preferably, the device also comprises a pretreatment device, the pretreatment device is a grating or a primary sedimentation tank, and the pharmaceutical wastewater to be treated is firstly treated by the pretreatment device and then is introduced into the monosulfate oxidation tank.
From the above description, it can be seen that the present invention has the following advantages:
(1) the method comprises the steps of firstly directly carrying out oxidative degradation on pharmaceutical wastewater to be treated by using peroxymonosulfate, removing antibiotic substances in the pharmaceutical wastewater, improving the biodegradability of the wastewater, then flocculating and settling the wastewater in a sedimentation tank under the action of a coagulant aid, and then sequentially enabling the wastewater to enter an anaerobic bioreactor and an MBR (Membrane bioreactor) coupled with an algae system for treatment.
(2) According to the invention, the microalgae and the light source are arranged in the MBR, so that the coupling of an algae system and the conventional MBR membrane bioreactor can be realized, and the microalgae and the activated sludge can form a symbiotic system under a proper condition, so that not only can the organic carbon in the water be deeply degraded, but also the removal effect of nitrogen, phosphorus and other nutrient substances in the water can be greatly improved.
(3) Compared with the traditional Fenton oxidation treatment process, the pharmaceutical wastewater is oxidized by using the non-activated peroxymonosulfate without adjusting the pH value of the wastewater, so that the treatment cost of the wastewater is reduced, the peroxymonosulfate is oxidized selectively, the influence of organic matters in the wastewater is avoided, and the reaction is efficient.
Detailed Description
The features of the invention will be further elucidated by the following examples, without limiting the claims of the invention in any way.
Example 1
A novel treatment device for pharmaceutical wastewater comprises a grating, a persulfate oxidation tank, a sedimentation tank, a UASB anaerobic bioreactor and an MBR membrane bioreactor which are sequentially arranged in series from upstream to downstream; the UASB anaerobic bioreactor is filled with a polyethylene plastic ring as a microorganism carrier, the MBR membrane bioreactor is provided with a light source and an aeration device, and the activated sludge in the MBR membrane reactor is uniformly distributed with microalgae.
The method for treating the pharmaceutical wastewater by adopting the device comprises the following steps:
(1) introducing the pharmaceutical wastewater to be treated after interception and filtration by the grid into a peroxymonosulfate oxidation tank, and then adding peroxymonosulfate into the peroxymonosulfate oxidation tank for reaction for 10min, wherein the pharmaceutical wastewater to be treated contains tetracycline, the concentration of the tetracycline is 10mg/L, and the adding amount of the peroxymonosulfate is 500 mu mol/L;
(2) using Ca (OH)2Adjusting the pH value of effluent of the peroxymonosulfate oxidation tank to 7-8 by using the suspension, adding polyacrylamide into the wastewater, wherein the adding amount of the polyacrylamide is 3mg/L, and fully stirring to enable the wastewater to enter a sedimentation tank for sedimentation for 25 min;
(3) introducing effluent of the sedimentation tank into a UASB anaerobic bioreactor, and carrying out anaerobic treatment under the conditions that the pH is 6.5-7.5 and the temperature is 35 ℃; wherein the inoculation ratio of anaerobic sludge in the UASB anaerobic bioreactor is 3: 1;
(4) introducing effluent of the anaerobic bioreactor into an MBR (membrane bioreactor) for treatment, and directly discharging the effluent, wherein the concentration of activated sludge in the MBR is 7g/L, and the mass ratio of microalgae to activated sludge is 10: 1; the membrane flux of the MBR membrane reactor is 8L/(m)2H), HRT (hydraulic retention time) of the MBR membrane reactor is 9h, and SRT (sludge retention time) of the sludge is 20 d; the aeration quantity in the MBR membrane reactor is controlled to be 2L/m3The illumination intensity of the light source is 300 mu mol/(m)2S) with a light-to-dark ratio of 12h to 12 h.
The wastewater in this example was distributed by laboratory water, and the water quality of the inlet and outlet water in each step of this example is shown in table 1:
TABLE 1
Example 2
The method for treating the pharmaceutical wastewater by adopting the device as in example 1 comprises the following steps:
(1) introducing the pharmaceutical wastewater to be treated after interception and filtration by the grid into a peroxymonosulfate oxidation pond, and then adding peroxymonosulfate into the peroxymonosulfate oxidation pond for reaction for 10min, wherein the pharmaceutical wastewater to be treated contains beta lactam, the concentration of the beta lactam is 30mg/L, and the adding amount of the peroxymonosulfate is 1000 mu mol/L;
(2) using Ca (OH)2Adjusting the pH value of effluent of the peroxymonosulfate oxidation tank to 7-8 by using the suspension, adding polyacrylamide into the wastewater, wherein the adding amount of the polyacrylamide is 3mg/L, and fully stirring to enable the wastewater to enter a sedimentation tank for sedimentation for 25 min;
(3) introducing effluent of the sedimentation tank into a UASB anaerobic bioreactor, and carrying out anaerobic treatment under the conditions that the pH is 6.5-7.5 and the temperature is 35 ℃; wherein the inoculation ratio of anaerobic sludge in the UASB anaerobic bioreactor is 3: 1;
(4) introducing effluent of the anaerobic bioreactor into an MBR (membrane bioreactor) for treatment, and directly discharging the effluent, wherein the concentration of activated sludge in the MBR is 7g/L, and the mass ratio of microalgae to activated sludge is 10: 1; the membrane flux of the MBR membrane reactor is 8L/(m)2H), HRT (hydraulic retention time) of the MBR membrane reactor is 9h, and SRT (sludge retention time) of the sludge is 20 d; the aeration quantity in the MBR membrane reactor is controlled to be 2L/m3The illumination intensity of the light source is 300 mu mol/(m)2S) with a light-to-dark ratio of 12h to 12 h.
The wastewater in this example is pharmaceutical wastewater from Shanghai, and the water quality of the inlet and outlet water in each step of this example is shown in Table 2:
comparative example 1
The same method as in example 2 was used, except that the mass ratio of microalgae to activated sludge was 9: 1. The water quality of the inlet and outlet water in each step of this example is shown in table 3:
comparative example 2
The same method as in example 2 was used, except that the mass ratio of microalgae to activated sludge was 11: 1. The water quality of the inlet and outlet water in each step of this example is shown in table 4:
it should be understood that the above detailed description of the present invention is only for illustrating the present invention and is not limited to the technical solutions described in the embodiments of the present invention. It will be appreciated by those skilled in the art that the present invention may be modified or substituted equally as well to achieve the same technical result; as long as the use requirements are met, the method is within the protection scope of the invention.
Claims (10)
1. A novel treatment device for pharmaceutical wastewater is characterized by comprising a peroxymonosulfate oxidation tank, a sedimentation tank, a UASB anaerobic bioreactor and an MBR membrane bioreactor which are sequentially connected in series from upstream to downstream; a light source and an aeration device are arranged in the MBR membrane bioreactor, and microalgae are uniformly distributed in the activated sludge in the MBR membrane bioreactor.
2. The method for treating pharmaceutical wastewater by using the device of claim 1, comprising the steps of:
(1) introducing the pharmaceutical wastewater to be treated into a peroxymonosulfate oxidation tank, and then adding peroxymonosulfate into the peroxymonosulfate oxidation tank for reaction;
(2) adjusting the pH of effluent of a peroxymonosulfate oxidation tank to 7-8 by adopting a pH regulator, then adding a coagulant aid into the wastewater, and after fully stirring, allowing the wastewater to enter a sedimentation tank for sedimentation for 20-30 min;
(3) introducing effluent of the sedimentation tank into a UASB anaerobic bioreactor, and carrying out anaerobic treatment under the conditions that the pH is 6.5-7.5 and the temperature is 35 ℃;
(4) and (3) introducing the effluent of the anaerobic bioreactor into an MBR (membrane bioreactor) for treatment, and directly discharging the effluent.
3. The method of claim 2, wherein the amount of the peroxymonosulfate added in step (1) is 100-1200 μmol/L, and the ratio of the amount of the peroxymonosulfate added to the initial concentration of the antibiotic in the pharmaceutical wastewater is 100 μmol/L (2-3) mg/L.
4. The method of claim 2, wherein the pH regulator in step (2) is HCl solution or Ca (OH)2And (4) suspending the solution.
5. The method according to claim 2, wherein the coagulant aid used in step (2) is polyacrylamide, and the amount of the coagulant aid added is 3 mg/L.
6. The method as claimed in claim 2, wherein the UASB anaerobic bioreactor in step (3) is filled with polyethylene plastic rings as microbial carriers.
7. The method of claim 2, wherein the concentration of the activated sludge in the MBR membrane reactor in the step (4) is 6-8 g/L, and the mass ratio of the microalgae to the activated sludge is 10: 1.
8. The method of claim 2, wherein the MBR membrane reactor in step (4) has a membrane flux of 6-10L/(m)2H), HRT (hydraulic retention time) of the MBR (membrane bioreactor) membrane reactor is 8-10 h, and SRT (sludge retention time)Is 15 to 25 days.
9. The method of claim 2, wherein the aeration rate in the MBR membrane reactor in step (4) is controlled to be 2L/m3The illumination intensity of the light source is 300 mu mol/(m)2S), light-to-dark ratio of 12h: and (4) 12 h.
10. The method of claim 2, wherein the apparatus further comprises a pretreatment device, the pretreatment device is a grid or a primary sedimentation tank, and the pharmaceutical wastewater to be treated is treated by the pretreatment device and then passed through a sulfate oxidation tank.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010659945.XA CN111995169A (en) | 2020-07-10 | 2020-07-10 | Novel treatment device and treatment method for pharmaceutical wastewater |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010659945.XA CN111995169A (en) | 2020-07-10 | 2020-07-10 | Novel treatment device and treatment method for pharmaceutical wastewater |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111995169A true CN111995169A (en) | 2020-11-27 |
Family
ID=73467437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010659945.XA Pending CN111995169A (en) | 2020-07-10 | 2020-07-10 | Novel treatment device and treatment method for pharmaceutical wastewater |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111995169A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113121036A (en) * | 2021-03-15 | 2021-07-16 | 太原理工大学 | Integrated device for degrading antibiotic wastewater by persulfate |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106746159A (en) * | 2015-11-19 | 2017-05-31 | 中国石油化工股份有限公司 | A kind of processing method of antibiotic production wastewater |
| CN108862848A (en) * | 2018-07-03 | 2018-11-23 | 秦皇岛格瑞因环境工程有限公司 | The treatment process and processing system of pharmacy waste water |
| US10138150B1 (en) * | 2018-01-18 | 2018-11-27 | Water Solutions, Inc. | Methods and systems for treating vinasse |
| CN110156135A (en) * | 2019-04-10 | 2019-08-23 | 同济大学 | A kind of method that peroxy-monosulfate removes tetracycline in livestock breeding wastewater |
| CN110436614A (en) * | 2019-08-02 | 2019-11-12 | 大连理工大学 | It is a kind of based on microalgae/activated sludge water treatment technology |
-
2020
- 2020-07-10 CN CN202010659945.XA patent/CN111995169A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106746159A (en) * | 2015-11-19 | 2017-05-31 | 中国石油化工股份有限公司 | A kind of processing method of antibiotic production wastewater |
| US10138150B1 (en) * | 2018-01-18 | 2018-11-27 | Water Solutions, Inc. | Methods and systems for treating vinasse |
| CN108862848A (en) * | 2018-07-03 | 2018-11-23 | 秦皇岛格瑞因环境工程有限公司 | The treatment process and processing system of pharmacy waste water |
| CN110156135A (en) * | 2019-04-10 | 2019-08-23 | 同济大学 | A kind of method that peroxy-monosulfate removes tetracycline in livestock breeding wastewater |
| CN110436614A (en) * | 2019-08-02 | 2019-11-12 | 大连理工大学 | It is a kind of based on microalgae/activated sludge water treatment technology |
Non-Patent Citations (1)
| Title |
|---|
| 彭党聪: "《水污染控制工程第3版》", 30 April 2000, 北京冶金工业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113121036A (en) * | 2021-03-15 | 2021-07-16 | 太原理工大学 | Integrated device for degrading antibiotic wastewater by persulfate |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amini et al. | Municipal wastewater treatment by semi-continuous and membrane algal-bacterial photo-bioreactors | |
| CN101560039B (en) | Landfill leachate wastewater treatment system and process thereof | |
| Fu et al. | Textiles wastewater treatment using anoxic filter bed and biological wriggle bed-ozone biological aerated filter | |
| KR101444642B1 (en) | Wastewater Treating Apparatus for Saving Energy Using Microalgae | |
| KR101444643B1 (en) | Wastewater Treating Apparatus Using Microalgae | |
| CN103232145A (en) | Method for degrading ammonia nitrogen in high-salinity sewage by microbes | |
| CN101654314A (en) | Dye waste water treatment method | |
| CN203976586U (en) | Printing and dyeing wastewater treatment system | |
| CN111087128A (en) | Treatment method for monoclonal antibody pharmaceutical wastewater | |
| CN105541005A (en) | Degradation-resistant salt chemical wastewater deep treatment method | |
| Laurent et al. | Finding optimal algal/bacterial inoculation ratio to improve algal biomass growth with wastewater as nutrient source | |
| CN111995169A (en) | Novel treatment device and treatment method for pharmaceutical wastewater | |
| CN108069570B (en) | Method for removing carbon, nitrogen and phosphorus in aquaculture wastewater | |
| CN111153551A (en) | Municipal sewage treatment device and treatment process | |
| CN104692592A (en) | Dye wastewater advanced treatment and recycling device and process | |
| KR100278798B1 (en) | Wastewater purification treatment apparatus and method using vertical rotary contact filtering method | |
| CN212687845U (en) | Pharmaceutical wastewater comprehensive treatment device | |
| CN204569649U (en) | The device of a kind of waste water from dyestuff advanced treatment and reuse | |
| CN112358041A (en) | Granular sludge culture method for synchronous denitrification and methanogenesis and COD removal | |
| CN112142254A (en) | High-concentration nitrogen-containing leather sewage treatment method and device based on composite microbial inoculum | |
| CN107601778B (en) | A method of utilizing laser reinforcing active sludge treatment organic wastewater | |
| CN221460084U (en) | DMF waste water's processing apparatus | |
| CN216273614U (en) | Purification tank for domestic sewage treatment | |
| CN220056588U (en) | Purification cyclic utilization system of eel breeding wastewater | |
| CN215712061U (en) | High-sludge-concentration low-dissolved-oxygen bio-multiplication sewage treatment device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201127 |